Irritable Bowel Syndrome (IBS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Irritable Bowel Syndrome (IBS) Market Outlook

Thelansis’s “Irritable Bowel Syndrome (IBS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Irritable Bowel Syndrome (IBS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Irritable Bowel Syndrome (IBS) Overview

Irritable bowel syndrome (IBS) is a prevalent medical condition characterized by chronic, recurrent abdominal pain, discomfort, and altered bowel habits. This condition occurs in the absence of other organic gastrointestinal (GI) diseases, and its underlying cause is still under investigation but is believed to involve multiple factors. The factors that may trigger disruptions in GI motor and sensory function include irritation from digestive byproducts, past gastroenteritis, internal irritants, gut microbiome changes, mucosal immune responses, food intolerance, and increased mucosal permeability. These underlying disruptions give rise to symptoms such as discomfort, gut motility changes, and bowel habit alterations. Genetic factors may also contribute to the development of IBS. BS can manifest with a wide array of gastrointestinal symptoms. While abdominal pain is one of the most common complaints, individuals with IBS may also experience bloating, a feeling of incomplete bowel emptying, urgency, diarrhea, straining, and constipation. The abdominal pain in IBS is typically crampy and varies in location and intensity. This pain is often associated with bowel movements, with some patients experiencing relief after bowel movements and others having worsening pain during them. Additionally, meals and emotional stress can exacerbate abdominal pain in some patients. Functional bowel disease experts established the Rome criteria to manage patients with abdominal symptoms resembling IBS. According to this classification, IBS is categorized based on the predominant stool pattern as follows:

1. IBS with predominant constipation (IBS-C): characterized by more than 25% hard stools and less than 25% loose stools.
2. IBS with predominant diarrhea (IBS-D): marked by more than 25% loose stools and less than 25% hard stools.
3. IBS with mixed bowel habits (IBS-M): characterized by more than 25% loose stools and more than 25% hard stools.
4. IBS unclassified (IBS-U): characterized by less than 25% loose stools and less than 25% hard stools.

The differential diagnosis for IBS is extensive. A comprehensive patient history, physical examination, and a few laboratory tests can help rule out conditions such as celiac disease, inflammatory bowel disease, microscopic colitis, post-cholecystectomy bile acid diarrhea, and small intestinal bacterial overgrowth (SIBO). Patients with IBS-C may also have pelvic floor dysfunction or colonic transit disorders. If treatment fails to alleviate symptoms, further evaluation may be necessary, including a rectal examination to identify patients with dyssynergia or pelvic floor issues. Management of IBS encompasses dietary adjustments, medication options, and mind-body treatments. The United States Food and Drug Administration (FDA) has approved two agents, lubiprostone and linaclotide, specifically for IBS-C treatment.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Irritable Bowel Syndrome (IBS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034